News

According to the companies, the collaboration has the potential to benefit patients who have suffered from specific, chronic ocular diseases.

A new survey shows that 95% of adults at risk for certain retinal diseases know a little or nothing about them. Allen hopes her story will help raise awareness and encourage those at risk to regularly prioritize their eye health.

According to the company, 4D-150 comprises its customized and evolved intravitreal vector, R100, and a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory RNAi.

Ocular Therapeutic, Rezolute, and Opthea will all present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City in September.

According to the company, it has 9 presentations at the annual congress of the European Society of Cataract and Refractive Surgeons being held in Vienna. AVG also is a sponsor of the International Society of Presbyopia.

The beauty brand announces Ashley Brissette, MD, MSc, FRCSC, will be the brand's first guiding ophthalmologist.

DMEI is 1 of only 17 centers in the US certified to provide this specialized treatment. Previously, patients in the region who qualified for LUXTURNA would have had to travel to other states to receive treatment.

According to the company, NFS-05, utilizes a gene therapy approach that delivers an AAV vector containing the OPA1 gene into the vitreous cavity.

According to the company, the deal expands its European footprint into Spain and Portugal.

The 6-month-old boy’s dark brown eyes turned deep blue after he was treated for COVID with favipiravir.

EyeSouth Partners has partnered with Retina and Vitreous of Texas, a retina-only practice in Houston, Texas. The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations.

According to the company, the tool provides free access to training and mentors for eye care professionals in areas with the greatest need, and the new Cybersight mobile app expands access for eye care professionals through offline functionality.

The experimental gene therapy was administered as a treatment in part of a randomized, partially masked, controlled, phase 3 clinical study evaluating the efficacy and safety of an experimental therapy, ABBV-RGX-314, for wet AMD.

We asked, "What research at ASRS 2023 do you find exciting or interesting?" Here's what Paul Hahn, MD, Kerrie Brady, BPharm, MBA, MS, and Michael Singer, MD had to say!

Our team spoke with several researchers and industry professionals at the 2023 American Society of Retina Specialists meeting in Seattle, Washington. We asked them, "What research here do you find exciting or interesting?" Here's what Tarek Hassan, MD, Nancy Lurker, and J. Fernando Arevalo, MD, PhD, FACS, FASRS, had to say!

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!

Prevent Blindness declares September as Sports Eye Safety Month to educate the public on the risk of significant eye injuries and the need for the proper sports eye protection.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!

According to the university, a special antibody that is derived from llamas, called a nanobody, can stop the misfolding and the activation of Rhodopsin, a molecule whose mutations can lead to blindness.

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin PhD, and Carl Danzig, MD had to say!

According to the Keck School of Medicine of USC, the $12.4 million from the California Institute for Regenerative Medicine is the latest round of support for USC researcher Mark Humayun and a milestone in the development of a stem cell patch to treat advanced dry age-related macular degeneration.

According to Outlook Therapeutics, it is working with the FDA to address the agency’s issues.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

More than 135 patients have been recruited in 4 months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 ophthalmic solution as an adjunct to standard-of-care surgery.

The research by Scott N J Watamaniuk, PhD, has potential implications for patients diagnosed with strabismus.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.